25 April

Sticky

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Condition Ovarian Neoplasms|Colorectal Neoplasms|Melanoma|Small Cell Lung Cancer|Liposarcoma Estimated Enrollment: 149 Age Group: 19 Years and older (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: 04-109 Study First Received: August 18, 2005 Last Updated: July 23, 2014 Estimated Primary Completion Date: July 2014 Primary Outcome Measures: apoptotic response Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00132704...

25 April

0 Comments

Sticky

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Posted by Goldberg, Persky & White P.C.

Condition Advanced Solid Tumors Estimated Enrollment: 60 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: OSI-930-103 Study First Received: December 26, 2007 Last Updated: September 26, 2011 Estimated Primary Completion Date: April 2010 Primary Outcome Measures: Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles|Safety, evaluate pharmacodynamic relationships Sponsors and Collaborators: Astellas Pharma Inc|OSI Pharmaceuticals Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00603356...

25 April

0 Comments

Sticky

Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy

Posted by Goldberg, Persky & White P.C.

Condition Pleural Effusion|Pleural Diseases Estimated Enrollment: 124 Age Group: 18 Years to 85 Years (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Primary Purpose: Diagnostic Study ID Numbers: 2007.11.008 Study First Received: July 21, 2008 Last Updated: July 22, 2008 Estimated Primary Completion Date: June 2008 Primary Outcome Measures: Efficacy and safety of both thoracoscopy and CT-guided pleural needle biopsy for diagnosis of pleural diseases|Determine the efficacy of pleural needle biopsy and thoracoscopy in relation to CT findings. Sponsors and Collaborators: Eskisehir Osmangazi University Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00720954...

25 April

0 Comments

Sticky

Rapamycin With Grapefruit Juice for Advanced Malignancies

Posted by Goldberg, Persky & White P.C.

Condition Tumors|Neoplasm Metastasis Estimated Enrollment: 41 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 14435B Study First Received: September 11, 2006 Last Updated: January 16, 2014 Estimated Primary Completion Date: May 2009 Primary Outcome Measures: Pharmacokinetic interaction Sponsors and Collaborators: University of Chicago Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00375245...

25 April

0 Comments

Sticky

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Posted by Goldberg, Persky & White P.C.

Condition Life Threatening Diseases Estimated Enrollment: 185 Age Group: 15 Years to 70 Years (Child, Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CSTI571B2225 Study First Received: September 9, 2005 Last Updated: November 16, 2016 Estimated Primary Completion Date: January 2007 Primary Outcome Measures: To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases|To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease|To assess the safety and tolerability of Imatinib mesylate|To evaluate the pharmacokinetic profile of Imatinib mesylate|To assess,...

25 April

0 Comments

Sticky

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Posted by Goldberg, Persky & White P.C.

Condition Tumor Estimated Enrollment: 35 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: PXD101-CLN-4 Study First Received: December 18, 2006 Last Updated: July 7, 2015 Estimated Primary Completion Date: March 2008 Primary Outcome Measures: to determine the maximum tolerated dose of PXD101 administered in combination with 5-FU|to determine whether PXD101 alone can down-regulate thymidylate synthase in patient tumors Sponsors and Collaborators: Onxeo Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00413322...

25 April

0 Comments

Sticky

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Posted by Goldberg, Persky & White P.C.

Condition Solid Tumor|Lymphoma Estimated Enrollment: 121 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: PXD101-CLN-9 Study First Received: December 18, 2006 Last Updated: July 7, 2015 Estimated Primary Completion Date: August 2011 Primary Outcome Measures: Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort|Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels|Explore anti-tumor activity|Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma Sponsors and Collaborators: Onxeo|Spectrum Pharmaceuticals, Inc Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00413075...

25 April

0 Comments

Sticky

E-MOSAIC Electronic Tool to Monitor Symptoms

Posted by Goldberg, Persky & White P.C.

Condition Cancer Estimated Enrollment: 264 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Study ID Numbers: SAKK 95/06|EU-20711 Study First Received: May 23, 2007 Last Updated: October 8, 2015 Estimated Primary Completion Date: January 2012 Primary Outcome Measures: Determine the effect of an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC) and a Longitudinal Monitoring Sheet (LoMoS) on global quality of life (G-QOL)|Determine if this tool affects communication between these patients and their treating physicians.|Determine if this tool affects the symptoms and syndromes reported by these patients|Determine if this tool impacts symptom management performance Sponsors and Collaborators: Swiss Group for...

25 April

0 Comments

Sticky

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

Posted by Goldberg, Persky & White P.C.

Condition Cancer Estimated Enrollment: null Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000270801|MSKCC-02080|NCI-1617 Study First Received: March 6, 2003 Last Updated: April 23, 2011 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00055705...

25 April

0 Comments

Sticky

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Posted by Goldberg, Persky & White P.C.

Condition Cancer Estimated Enrollment: 75 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 010124|01-C-0124|NCI-2792|CDR0000068615 Study First Received: July 11, 2001 Last Updated: March 14, 2012 Estimated Primary Completion Date: April 2008 Primary Outcome Measures: Dose-limiting toxicities and maximum tolerated dose|Pharmacology and pharmacokinetics|Acetylation of histones in peripheral blood|Tumor response by CT scan every 12 weeks Sponsors and Collaborators: National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00020579...

Archive

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy

Rapamycin With Grapefruit Juice for Advanced Malignancies

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

E-MOSAIC Electronic Tool to Monitor Symptoms

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Recent articles

About Goldberg, Persky & White P.C. Law Firm